We are initiating coverage of Resverlogix Corp. (RVX.TO) (RVXCF) with a "Hold" rating and a $3.25 price target. Resverlogix Corp. is a clinical stage cardiovascular company with an epigenetic platform ...
Resverlogix Corp. Annual stock financials by MarketWatch. View the latest RVX financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback